Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immunodeficiency virus-associated dementia.

D B Clifford1

  • 1Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA. Cliffordd@neuro.wustl.edu

Archives of Neurology
|March 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024
Same author

Checkpoint therapy for progressive multifocal leukoencephalopathy: pointless?

European journal of neurology·2020
Same author

Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection.

Molecular neurobiology·2018
Same author

Brain morphometric correlates of metabolic variables in HIV: the CHARTER study.

Journal of neurovirology·2014
Same author

Characterizing HIV medication adherence for virologic success among individuals living with HIV/AIDS: Experience with the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) cohort.

Journal of HIV/AIDS & social services·2014
Same author

Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders.

Journal of neurovirology·2013
Same journal

Incorrect Table Entries and Word.

Archives of neurology·2016
Same journal

IDEAL for CCSVI Research-Reply.

Archives of neurology·2013
Same journal

Atlas of Inherited Metabolic Diseases, 3rd ed.

Archives of neurology·2013
Same journal

Error in byline: in heterogeneity of coenzyme q10 deficiency: patient study and literature review.

Archives of neurology·2013
Same journal

This month in archives of neurology.

Archives of neurology·2013
Same journal

About this journal.

Archives of neurology·2013
See all related articles

Optimal control of human immunodeficiency virus (HIV) infection with antiretroviral therapy significantly benefits neurologic manifestations. Further research is needed to improve central nervous system (CNS) HIV therapy and neuroprotection strategies.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Pharmacology

Background:

  • Antiretroviral therapy (ART) has improved outcomes for patients with human immunodeficiency virus (HIV).
  • Neurologic manifestations of HIV infection remain a significant challenge despite advances in systemic treatment.
  • The central nervous system (CNS) compartment presents unique challenges for drug delivery and therapeutic efficacy.

Purpose of the Study:

  • To review the impact of optimal HIV control on neurologic disease.
  • To highlight the need for research into CNS HIV pathophysiology and enhanced drug delivery.
  • To discuss the ongoing search for effective neuroprotective agents in HIV-associated neurocognitive disorders.

Main Methods:

  • Review of current literature on HIV therapy and its effects on CNS manifestations.

Related Experiment Videos

  • Analysis of the challenges in delivering antiretroviral drugs to the CNS.
  • Discussion of clinical trials and outcomes of neuroprotective agents.

    • Main Results:

    • Optimal ART has led to a decline in the incidence of HIV-associated neurologic disease.
    • No neuroprotective treatment has yet demonstrated definitive clinical benefit.
    • Improved HIV management increases patient lifespan, potentially increasing the prevalence of age-related neurologic complications.

    Conclusions:

    • While ART has improved HIV-associated neurologic disease, CNS-targeted therapies remain a critical frontier.
    • Further research is essential to understand CNS HIV pathophysiology and optimize therapeutic strategies.
    • Developing effective neuroprotection is crucial for long-term management of HIV patients.